4.5 Article

The Longitudinal Outcome of Fibromyalgia: A Study of 1555 Patients

Journal

JOURNAL OF RHEUMATOLOGY
Volume 38, Issue 10, Pages 2238-2246

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.110026

Keywords

FIBROMYALGIA; OUTCOME; IMPROVEMENT

Categories

Funding

  1. Bristol-Myers Squibb
  2. Jazz Pharmaceuticals
  3. Boehringer Ingelheim
  4. Eli-Lilly
  5. Paladin
  6. Pfizer
  7. Purdue

Ask authors/readers for more resources

Objective. To describe the diagnosis status and outcome of patients diagnosed with fibromyalgia (FM) by US rheumatologists. Methods. We assessed 1555 patients with FM with detailed outcome questionnaires during 11,006 semiannual observations for up to 11 years. At entry, all patients satisfied American College of Rheumatology preliminary 2010 FM criteria modified for survey research. We determined diagnosis status, rates of improvement, responder subgroups, and standardized mean differences (effect sizes) between start and study completion scores of global well-being, pain, sleep problems, and health related quality of life. (QOL) Results. The 5-year improvement rates were pain 0.4 (95% CI 0.2, 0.5), fatigue 0.4 (95% CI 0.2, 0.05), and global 0.0 (95% CI -0.1, 0.1). The standardized mean differences were patient global 0.03 (95% CI -0.02,0.08), pain 0.22(95% CI 0.16, 0.28), sleep problems 0.20(95% CI 0.14, 0.25), physical component summary of the Short-form 36 (SF-36) 0.11(95% CI -0.14, -0.07), and SF-36 mental component summary 0.03 (95% CI -0.07,0.02). Patients switched between criteria-positive and criteria-negative states, with 716 patients (44.0%) failing to meet criteria at least once during 4228.5 patient-years (7448 observations). About 10% of patients had substantial improvement and about 15% had moderate improvement of pain. Overall, FM severity worsened in 35.9% and pain in 38.6%. Conclusion. Although we found no average clinically meaningful improvement in symptom severity overall, 25% had at least moderate improvement of pain over time. The result that emerged from this longitudinal study was one of generally continuing high levels of self-reported symptoms and distress for most patients, but a slight trend toward improvement. (First Release July 15 2011; J Rheumatol 2011;38:2238-46; doi:10.3899/jrheum.110026)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available